Tags : License

Henlius Signs a License Agreement with Essex to Co-develop HLX04

Shots: Henlius to receive upfront, regulatory, and commercial milestone payments of ~$43M, eligible to receive $30M for every $1B above the first $600M of the cumulative net sales along with 10% royalties on net sales of the therapy Henlius will be responsible for the pre/ clinical development of HLX04, whereas Essex is responsible for regulatory […]Read More

BMS Exercises its Option to Globally License Obsidian’s CD40L Cell

Shots: BMS has exercised its option to an exclusive WW license to a cell therapy based on Obsidian’s cytoDRiVE technology for the controlled expression of the immunomodulatory factor CD40L In 2019, the companies collaborated to develop novel cell therapies, under which Obsidian is eligible to receive milestones and royalties on sales of therapies. Exercising the […]Read More

AbbVie to License I-Mab’s Lemzoparlimab (TJC4) for ~$2B

Shots: I-Mab to receive $180M upfront, $20M on P-I results, and is eligible to receive ~$1.74B which include $840M as development & regulatory milestones while remaining as commercial milestones along with royalties on sales of the therapy outside China AbbVie to get an exclusive global license (Ex-greater China) to develop and commercialize lemzoparlimab while I-Mab […]Read More

AbbVie Exercises its Option to License Morphosys’ αvβ6 Integrin Inhibitor

Shots: Morphic will receive a $20M as license fee and is eligible to receive milestones and royalties on sales of any commercialized therapy while AbbVie has exercised a license option under the companies’ R&D collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for fibrotic diseases including IPF and additional indications The license covers αvβ6 integrin […]Read More

BeiGene Signs a License and Supply Agreement with Bio-Thera for

Shots: Bio-Thera to receive $165M upfront, regulatory, and commercial milestones and is eligible to receive royalties on sales of the product. BeiGene to get the right to develop, manufacture, and commercialize BAT1706 in China, including Hong Kong, Macau, and Taiwan while Bio-Thera will retain rights for the therapy outside the licensed territory The NMPA has […]Read More

Abeona Signs a License and Inventory Purchase Agreements with Taysha

Shots: Abeona to receive $7M including $3M up front, $4M inventory purchase price, including GMP-sourced CLN1 plasmid and is eligible to receive $56M as clinical, regulatory, and commercial milestones along with royalties on sales of ABO-202 Taysha gets an exclusive WW right to IP developed by scientists at the UNC and Abeona and Abeona know-how […]Read More

Sangamo Signs a Worldwide License Agreement with Novartis to Develop

Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales of the product. Additionally, Sangamo to take care of certain research and manufacturing activities funded by Novartis Novartis to get exclusive license rights of ZFP-TFs […]Read More

Bio-Thera Signs a License Agreement with Pharmapark for BAT2506 (golimumab,

Shots: Bio-Thera will take care of full development, and commercial supply of BAT2506 out of the manufacturing facilities in Guangzhou, China. Additionally, the agreement will utilize Pharmapark’s local presence, sales, and marketing capabilities in Russia and other CIS countries Pharmapark to get exclusive rights to distribute and market the product in Russia and other CIS […]Read More

BMS Signs an Exclusive Option to License Agreement with Dragonfly

Shots: Dragonfly to receive $55M upfront, additional payments for development, regulatory and sales milestones plus royalties on sales of approved products. BMS to get exclusive option to license exclusive worldwide IPR for multiple candidates developed using Dragonfly’s platform for multiple new targets The focus of the agreement is to expand the collaboration b/w the companies […]Read More

Sarepta Signs an Exclusive Worldwide License with Hansa to Develop

Shots: Hansa to receive $10M up front, up to $397.5M as development, regulatory & commercial milestones. Hansa will book all sales of therapy and will get royalties on gene therapy sales that arises from treating Ab-positive patients enabled through imlifidase pre-treatment Sarepta get an exclusive WW license to develop and promote imlifidase as a pre-treatment […]Read More